$60 Million

Krystal Biotech

Follow-on Offering

Lead Left Bookrunner, October 2018

Krystal Biotech
Krystal Biotech, Inc. is a clinical-stage gene therapy company dedicated to developing novel "off-the-shelf" treatments for dermatological diseases. Krystal's proprietary Skin TARgeted Delivery (STAR-D) platform consists of a patented engineered viral vector based on herpes simplex virus 1 (HSV-1) and its skin-optimized gene transfer technology. Krystal's lead product candidate, KB103, is a gene therapy in Phase I/II clinical development for the treatment of dystrophic epidermolysis bullosa (DEB). The Company is initially pursuing treatments for monogenic orphan indications and plans to expand into conditions with larger patient populations